



THE UNIVERSITY
of EDINBURGH



The
Fleming Fund



2025 Fleming Fund Fellowships Symposium

Friday 31st January, 9.00 to 17.00

Playfair Library, Old College



Edinburgh
Infectious
Diseases



Programme & Schedule

This event highlights work at University of Edinburgh as a Host Institution for the Fleming Fund Fellowship Schemes in Eastern and Southern Africa. Over the past 5 years University of Edinburgh Mentors have supported nearly 60 Fellows in Uganda, Kenya, Malawi and Zambia to build capacity that addresses the global challenges of antimicrobial resistance and responsible antibiotic use. Fellows take a One Health approach, to draw together inputs from human, animal and environmental sectors and develop cross-cutting, impactful and just solutions that can tackle the rise in resistant infections.

Our symposium brings together over 70 AMR specialists, including Fleming Fund Fellows from Kenya, Malawi and Uganda, Fleming Fund Academic Mentors, Researchers and Clinicians from the University of Edinburgh and members of the wider global AMR community. The programme will also feature networking opportunities between talks, and a round table discussion involving speakers and the audience.

09:30	Till Bachmann - University of Edinburgh	<i>Welcome and introductions</i>
09:45	Eileen Chappell - Mott MacDonald	<i>'The Fleming Fellowship Scheme: What next?'</i>
10:00	Sharon Pflieger – One Health Breakthrough Partnership	<i>"One Health or no health- why caring for our environment and animals keeps us healthy and drives down AMR"</i>
10:30	Jonathan Edgeworth - Oxford Nanopore Technologies Fatima Ulhuq - NHS Lothian	<i>Nanopore technologies in low-resource settings</i>
11:00	Coffee	
11:30	Evetta Chisope, Mphatso Kanjiru , Lecollins Mthilakuwili, Mark Mwalabu, Brighton Nkunika	<i>Malawi perspective: Impacts of AMR (Local to Global)</i>
11:50	Nehemiah Birgen, Cidee Khaseke, Gathira Muchira, Mercy Runya, Emmanuel Tanui	<i>Building reliable and robust AMR datasets in Kenya</i>
12:10	Laura Lydia Adong, Moses Mukembo, Dennis Nankoola	<i>Evidence-led practice and/or policy to meet the AMR challenge in Uganda</i>
12:30	Lunch	
13:30	Macaulay Jones – World Farmers' Organisation	<i>Putting farmers at the heart of AMR policy</i>
14:00	Gabriel Pedone - BioMérieux	<i>Diagnostics and Antimicrobial Resistance: Turning Challenges into Opportunities in LMICs</i>
14:30	Coffee	
15:00	Praise Chilanga, Upile Kachepa, Kelvin Maziya, Tawina Tenthani	<i>Evidence-led practice and/or policy to meet the AMR challenge in Malawi.</i>
15:20	Paul Ayieko, Eve Koile, Alexina Kwamboka, John Mumbo, Caroline Wafula	<i>Community & stakeholder engagement in Kenya</i>
15:40	Alison Prendeville – University of Arts London	<i>Service Design's contribution to AMR</i>
16:10	Roundtable discussion	<i>One Health Approach to AMR</i>

Keynote Speakers Biographies



Professor Till Bachmann is the Chair of Molecular Diagnostics and Infection at the Centre of Inflammation Research at University of Edinburgh. Till is the AMR Strategy Lead for Edinburgh Infectious Diseases, Chair of the Edinburgh AMR Forum, and Co-Director of the University of Edinburgh's Fleming Fund Fellowships Host Institution programme.

Till fulfils a range of industrial and institutional advisory roles worldwide including with WHO, Quadripartite, Global AMR R&D Hub, Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), Longitude Prize on Antibiotics, BEAM Alliance, Pathways to Antimicrobial Clinical Efficacy (PACE). He is an expert in point of care detection of infectious diseases and antimicrobial resistance, conducting research on the development, implementation and impact of rapid diagnostics in a One Health and Global Health context.



Eileen Chappell is the Fellowships Programme Lead for the Fleming Fund programme funded by the UK Government Department of Health and Social Care. She has been running the fellowship programme since 2018 when she was invited to join the Fleming Fund team by Mott MacDonald who are the management agent. Prior to the Fleming Fund, Eileen joined the London School of Hygiene and Tropical Medicine in 1997, working first as a manager in the Clinical Research Unit and from 2000 in the Environmental Health Unit, where from 2009 she was the Chief Executive Officer of a large DFID consortium on WASH and behaviour change in schools and institutions in Africa and South Asia. Eileen has specialised in running capacity development programmes and mentoring in every aspect of her career including in her early career as an archaeological scientist working on organic residue analysis as well as field archaeology.



Professor Sharon Pflieger currently works in NHS Highland as a Consultant in Pharmaceutical Public Health using her dual registration as a pharmacist and as a public health specialist focussing on the use of medicines at a population level- developing policy and practice covering anything that involves the use of a medicine from "postcode prescribing", vaccination, emergency planning, value for money and making difficult decisions in healthcare. Throughout the pandemic she was Programme Lead for Vaccines helping to plan the COVID vaccination programme in the Highlands.

Some years ago, she became acutely aware that healthcare, especially the use of medicines, is impacting on the environment and contributing to climate change and driving antimicrobial resistance (AMR) which is damaging not only the planet's health but that of our public too. This led her to become a founding member and NHS Highland/ Scotland lead of The One Health Breakthrough Partnership (<https://ohbp.org/>) working to reduce the impact of pharmaceuticals on the water environment, drive down AMR and make healthcare more sustainable.



Professor Jonathan Edgeworth's clinical work focusses on prevention, diagnosis and management of bacterial infections, particularly those due to antimicrobial resistant bacteria or that develop in people while in hospital. He is Director of the Centre for Clinical Infection and Diagnostics Research (CIDR) at Kings College London and Guy's and St Thomas' Hospital. The centre hosts academic clinicians, scientists, epidemiologists and research nurses focussed on epidemiology, surveillance and prevention of infections due to multi-drug-resistant bacteria, development an evaluation of novel diagnostics, and clinical studies that improve the evidence base for effective use of antibiotics. Jonathan has also been an active researcher for over 30 years. He started doing basic research to understand how bacteria cause disease and how we fight infection, but since joining the Trust in 2002 he has focussed on MRSA and more recently multi-drug-resistant Gram-negative bacteria (MDR-GNB) such as *E. coli*, *Klebsiella* and *Pseudomonas*.



Dr. Fatima Ulhuq is an Associate Clinical Scientist with NHS Lothian. She carried out her PhD on protein secretion systems in *S. aureus* on the BBSRC EASTBIO Doctoral Training Partnership at the University of Dundee. She then worked as a Postdoctoral Research Associate at Newcastle University before taking up her current role with NHS Lothian in November 2021.





Macaulay Jones is a Berlin-based independent consultant specialising in agriculture, sustainability, and trade policy. He has experience across a broad spectrum of policy matters vital to farmers and the primary sector, including working for over five years at Federated Farmers of New Zealand. A key piece of Macaulay's work is serving as the Scientific Council Liaison Officer at the World Farmers Organisation (WFO). The WFO is the world's largest independent farmer organisation, representing over 80 national farming organisations from over 50 countries.



Gabriel Pedone serves as the Global Health Strategic Partnering Director at bioMérieux, where he oversees business development activities and fosters relationships with international funding organizations. Over the past 30 years, he has held various senior international management roles in sales and marketing within the In Vitro Diagnostics (IVD) sector, consistently delivering impactful results across diverse markets. As bioMérieux's Immunoassays Director, Gabriel has played a pivotal role in shaping the company's strategy for low- and middle-income countries (LMICs) in Asia-Pacific, Africa, and Latin America. His efforts have focused on addressing critical healthcare challenges by tailoring diagnostic solutions to meet the unique needs of these regions.

Gabriel is deeply passionate about improving global health and is fully committed to advancing sustainable solutions to tackle healthcare challenges in resource-limited settings. He actively collaborates with international organizations, working upstream to help design and implement tailored programs for LMICs in a highly professional and impactful manner. His enthusiasm for working alongside multidisciplinary and multicultural teams drives his ability to foster innovation, align diverse expertise, and deliver meaningful outcomes.

As the leader of the Fleming Fund program management at bioMérieux, Gabriel leverages his extensive knowledge of LMIC environments and IVD systems to drive the successful deployment and implementation of bioMérieux solutions in reference laboratories worldwide. His expertise is a cornerstone in the global fight against antimicrobial resistance (AMR), strengthening laboratory capacities and public health systems in resource-constrained settings.



Dr Alison Prendiville is professor of Service Design at London College of Communication, University of the Arts London. Her research is transdisciplinary and transverses science and technology innovation with a focus on open, socially responsive co-design processes, with communities in the areas of human and animal health systems.

The focus of her design research is on service transformation, with her most recent work addressing the global health challenge of AMR (anti-microbial resistance) in UK nursing practices as well as in India under a One-Health approach in the development of diagnostics. Alison has a keen interest in understanding the contribution of design as a means of co-creating and translating knowledge between diverse actors, particularly when dealing with complex entangled societal challenges. She has contributed to numerous chapters in books and has co-edited and co-authored chapters in the recently published 2017, 'Designing for Service: Key Issues and New Directions'.

The Fleming Fund

The Fleming Fund is a UK aid programme supporting up to 25 countries across Africa and Asia to tackle antimicrobial resistance. The Fund is managed by the Department of Health and Social Care and invests in strengthening surveillance systems through a portfolio of country and regional grants, global projects and fellowship schemes.

The UK Government established the programme in 2015 in response to the UK AMR Review and the WHO Global Action Plan on AMR, which called for funding to improve AMR surveillance, public awareness and responsible drug use. The programme focuses on low- and middle-income (LMIC) countries because they are expected to bear the heaviest consequences of the spread of AMR. The UK AMR Review estimated that by 2050, up to 90% of all deaths related to AMR will come from Africa and Asia.

The Fleming Fund is named after Sir Alexander Fleming, the scientist who discovered penicillin and contributed to the development of the world's first antibiotic drug.